KAPA - CONSENSUS CO - Kairos Pharma Ltd

Kairos Pharma Ltd (KAPA) is optimizing the development of antitumor agents by delegating initial trials to external laboratories to minimize operational risks. The business focuses on creating drugs that eliminate tumor resistance to therapy within the immuno-oncology segment, where the metric stands at 49.06. This price chart, which serves as confirmation of the market valuation, complements the profile of an innovator developing solutions to activate the body's defenses against the most aggressive forms of cancer.

This indicator represents a weighted average fair value assessment of the asset over a one-year horizon, aggregating institutional expert expectations regarding the issuer's creditworthiness and capitalization. The current consensus price target reflects the market's sensitivity to the clinical trial results of Kairos Pharma (KAPA), where the risk of early-stage FDA failures and a high probability of equity dilution directly adjust target levels.